Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity

Drug resistance and tumor heterogeneity limits the therapeutic efficacy in treating glioblastoma, an aggressive infiltrative type of brain tumor. GBM cells develops resistance against chemotherapeutic agent, temozolomide (TMZ), which leads to the failure in treatment strategies. This enduring challe...

Descripción completa

Detalles Bibliográficos
Autores principales: Doan, Phuong, Nguyen, Phung, Murugesan, Akshaya, Candeias, Nuno R., Yli-Harja, Olli, Kandhavelu, Meenakshisundaram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393831/
https://www.ncbi.nlm.nih.gov/pubmed/34440745
http://dx.doi.org/10.3390/cells10081975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393831/
https://www.ncbi.nlm.nih.gov/pubmed/34440745
http://dx.doi.org/10.3390/cells10081975

Ejemplares similares